Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Five-year follow-up of transvenous and epicardial left ventricular leads: experience with more than 1000 leads.

Burger H, Pecha S, Hakmi S, Opalka B, Schoenburg M, Ziegelhoeffer T.

Interact Cardiovasc Thorac Surg. 2020 Jan 1;30(1):74-80. doi: 10.1093/icvts/ivz239.

PMID:
31633187
2.

Precipitation with polyethylene glycol followed by washing and pelleting by ultracentrifugation enriches extracellular vesicles from tissue culture supernatants in small and large scales.

Ludwig AK, De Miroschedji K, Doeppner TR, Börger V, Ruesing J, Rebmann V, Durst S, Jansen S, Bremer M, Behrmann E, Singer BB, Jastrow H, Kuhlmann JD, El Magraoui F, Meyer HE, Hermann DM, Opalka B, Raunser S, Epple M, Horn PA, Giebel B.

J Extracell Vesicles. 2018 Oct 17;7(1):1528109. doi: 10.1080/20013078.2018.1528109. eCollection 2018.

3.

Expansion of functional personalized cells with specific transgene combinations.

Lipps C, Klein F, Wahlicht T, Seiffert V, Butueva M, Zauers J, Truschel T, Luckner M, Köster M, MacLeod R, Pezoldt J, Hühn J, Yuan Q, Müller PP, Kempf H, Zweigerdt R, Dittrich-Breiholz O, Pufe T, Beckmann R, Drescher W, Riancho J, Sañudo C, Korff T, Opalka B, Rebmann V, Göthert JR, Alves PM, Ott M, Schucht R, Hauser H, Wirth D, May T.

Nat Commun. 2018 Mar 8;9(1):994. doi: 10.1038/s41467-018-03408-4.

4.

Gfi1b: a key player in the genesis and maintenance of acute myeloid leukemia and myelodysplastic syndrome.

Thivakaran A, Botezatu L, Hönes JM, Schütte J, Vassen L, Al-Matary YS, Patnana P, Zeller A, Heuser M, Thol F, Gabdoulline R, Olberding N, Frank D, Suslo M, Köster R, Lennartz K, Görgens A, Giebel B, Opalka B, Dührsen U, Khandanpour C.

Haematologica. 2018 Apr;103(4):614-625. doi: 10.3324/haematol.2017.167288. Epub 2018 Jan 11.

5.

Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a Growth factor independence 1 dependent manner.

Al-Matary YS, Botezatu L, Opalka B, Hönes JM, Lams RF, Thivakaran A, Schütte J, Köster R, Lennartz K, Schroeder T, Haas R, Dührsen U, Khandanpour C.

Haematologica. 2016 Oct;101(10):1216-1227. Epub 2016 Jul 7.

6.

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome.

Botezatu L, Michel LC, Makishima H, Schroeder T, Germing U, Haas R, van der Reijden B, Marneth AE, Bergevoet SM, Jansen JH, Przychodzen B, Wlodarski M, Niemeyer C, Platzbecker U, Ehninger G, Unnikrishnan A, Beck D, Pimanda J, Hellström-Lindberg E, Malcovati L, Boultwood J, Pellagatti A, Papaemmanuil E, Le Coutre P, Kaeda J, Opalka B, Möröy T, Dührsen U, Maciejewski J, Khandanpour C.

Exp Hematol. 2016 Jul;44(7):590-595.e1. doi: 10.1016/j.exphem.2016.04.001. Epub 2016 Apr 11.

7.

Cytomegalovirus induces apoptosis in acute leukemia cells as a virus-versus-leukemia function.

Koldehoff M, Lindemann M, Opalka B, Bauer S, Ross RS, Elmaagacli AH.

Leuk Lymphoma. 2015;56(11):3189-97. doi: 10.3109/10428194.2015.1032968. Epub 2015 May 15.

PMID:
25818505
8.

Complementation of non-tumorigenicity of HPV18-positive cervical carcinoma cells involves differential mRNA expression of cellular genes including potential tumor suppressor genes on chromosome 11q13.

Kehrmann A, Truong H, Repenning A, Boger R, Klein-Hitpass L, Pascheberg U, Beckmann A, Opalka B, Kleine-Lowinski K.

Cancer Genet. 2013 Jul-Aug;206(7-8):279-92. doi: 10.1016/j.cancergen.2013.06.002. Epub 2013 Sep 14.

PMID:
24042169
9.

Pluripotent stem cells escape from senescence-associated DNA methylation changes.

Koch CM, Reck K, Shao K, Lin Q, Joussen S, Ziegler P, Walenda G, Drescher W, Opalka B, May T, Brümmendorf T, Zenke M, Saric T, Wagner W.

Genome Res. 2013 Feb;23(2):248-59. doi: 10.1101/gr.141945.112. Epub 2012 Oct 18.

10.

Telomeres and prognosis in patients with chronic lymphocytic leukaemia.

Sellmann L, de Beer D, Bartels M, Opalka B, Nückel H, Dührsen U, Dürig J, Seifert M, Siemer D, Küppers R, Baerlocher GM, Röth A.

Int J Hematol. 2011 Jan;93(1):74-82. doi: 10.1007/s12185-010-0750-2. Epub 2011 Jan 5.

PMID:
21203871
11.

Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients.

Schütt P, Schütt B, Switala M, Bauer S, Stamatis G, Opalka B, Eberhardt W, Schuler M, Horn PA, Rebmann V.

Hum Immunol. 2010 May;71(5):489-95. doi: 10.1016/j.humimm.2010.02.015. Epub 2010 Mar 10.

PMID:
20156510
12.

Gene Therapy of βc-Deficient Pulmonary Alveolar Proteinosis (βc-PAP): Studies in a Murine in vivo Model.

Kleff V, Sorg UR, Bury C, Suzuki T, Rattmann I, Jerabek-Willemsen M, Poremba C, Flasshove M, Opalka B, Trapnell B, Dirksen U, Moritz T.

Mol Ther. 2008 Apr;16(4):757-764. doi: 10.1038/mt.2008.7. Epub 2016 Dec 8.

PMID:
28178466
13.

The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients.

Schütt P, Rebmann V, Brandhorst D, Wiefelspütz J, Ebeling P, Opalka B, Seeber S, Nowrousian MR, Moritz T, Grosse-Wilde H.

Hum Immunol. 2008 Feb;69(2):79-87. doi: 10.1016/j.humimm.2008.01.006. Epub 2008 Feb 7.

PMID:
18361931
14.

Gene therapy of beta(c)-deficient pulmonary alveolar proteinosis (beta(c)-PAP): studies in a murine in vivo model.

Kleff V, Sorg UR, Bury C, Suzuki T, Rattmann I, Jerabek-Willemsen M, Poremba C, Flasshove M, Opalka B, Trapnell B, Dirksen U, Moritz T.

Mol Ther. 2008 Apr;16(4):757-64. doi: 10.1038/mt.2008.7. Epub 2008 Mar 4.

15.

Therapeutic transfer of DNA encoding adenoviral E1A.

Deissler H, Opalka B.

Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):1-10. Review.

PMID:
18221050
16.

Interaction of Adenovirus E1A with the HHV8 Promoter of Latent Genes: E1A Proteins are Able to Activate the HHV-8 LANAp in MV3 Reporter Cells.

Koehler-Hansner K, Flore O, Opalka B, Hengge UR.

Open Virol J. 2008;2:61-8. doi: 10.2174/1874357900802010061. Epub 2008 Jul 7.

17.

O6-methylguanine-DNA-methyltransferase (MGMT) gene therapy targeting haematopoietic stem cells: studies addressing safety issues.

Sorg UR, Kleff V, Fanaei S, Schumann A, Moellmann M, Opalka B, Thomale J, Moritz T.

DNA Repair (Amst). 2007 Aug 1;6(8):1197-209. Epub 2007 May 11.

PMID:
17499560
18.

Reliable generation of stable high titer producer cell lines for gene therapy.

Rattmann I, Kleff V, Feldmann A, Ludwig C, Sorg UR, Opalka B, Moritz T, Flasshove M.

Intervirology. 2007;50(3):197-203. Epub 2007 Feb 2.

PMID:
17283445
19.

Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients.

Rebmann V, Schütt P, Brandhorst D, Opalka B, Moritz T, Nowrousian MR, Grosse-Wilde H.

Clin Immunol. 2007 Apr;123(1):114-20. Epub 2007 Jan 10.

PMID:
17218152
20.

Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia.

Eisele L, Klein-Hitpass L, Chatzimanolis N, Opalka B, Boes T, Seeber S, Moritz T, Flasshove M.

Acta Haematol. 2007;117(1):8-15. Epub 2006 Nov 8.

PMID:
17095854
21.

Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections.

Schütt P, Brandhorst D, Stellberg W, Poser M, Ebeling P, Müller S, Buttkereit U, Opalka B, Lindemann M, Grosse-Wilde H, Seeber S, Moritz T, Nowrousian MR.

Leuk Lymphoma. 2006 Aug;47(8):1570-82.

PMID:
16966269
22.

Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine transplant model.

Rattmann I, Kleff V, Sorg UR, Bardenheuer W, Brueckner A, Hilger RA, Opalka B, Seeber S, Flasshove M, Moritz T.

Blood. 2006 Nov 1;108(9):2965-71. Epub 2006 Jul 11.

PMID:
16835384
23.

Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.

Nowrousian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P, Poser M, Mueller S, Ebeling P, Welt A, Bradwell AR, Buttkereit U, Opalka B, Flasshove M, Moritz T, Seeber S.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8706-14.

24.

In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment.

Schütt P, Buttkereit U, Brandhorst D, Lindemann M, Schmiedl S, Grosse-Wilde H, Seeber S, Nowrousian MR, Opalka B, Moritz T.

Cancer Immunol Immunother. 2005 May;54(5):506-12. Epub 2004 Nov 20.

PMID:
15750834
25.

WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells.

Elmaagacli AH, Koldehoff M, Peceny R, Klein-Hitpass L, Ottinger H, Beelen DW, Opalka B.

Haematologica. 2005 Mar;90(3):326-34.

26.

Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.

Schütt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Poser M, Müller S, Flasshove M, Moritz T, Seeber S, Nowrousian MR.

Ann Hematol. 2005 Sep;84(9):594-600. Epub 2005 Mar 3.

PMID:
15744524
27.

Monoclonal antibody-polyethyleneimine conjugates targeting Her-2/neu or CD90 allow cell type-specific nonviral gene delivery.

Strehblow C, Schuster M, Moritz T, Kirch HC, Opalka B, Petri JB.

J Control Release. 2005 Feb 16;102(3):737-47.

PMID:
15681094
28.

Cellular in vitro immune function in multiple myeloma patients after high-dose chemotherapy and autologous peripheral stem cell transplantation.

Lindemann M, Schuett P, Moritz T, Ottinger HD, Opalka B, Seeber S, Nowrousian MR, Grosse-Wilde H.

Leukemia. 2005 Mar;19(3):490-2. No abstract available.

PMID:
15674357
29.

Prognostic relevance of fragile histidine triad protein expression in patients with small cell lung cancer.

Rohr UP, Rehfeld N, Geddert H, Pflugfelder L, Bruns I, Neukirch J, Rohrbeck A, Grote HJ, Steidl U, Fenk R, Opalka B, Gabbert HE, Kronenwett R, Haas R.

Clin Cancer Res. 2005 Jan 1;11(1):180-5.

30.

Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.

Schütt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Hoiczyk M, Flasshove M, Hense J, Bojko P, Metz K, Moritz T, Seeber S, Nowrousian MR.

Eur J Haematol. 2005 Jan;74(1):40-6.

PMID:
15613105
31.

Non-small lung cancer cells are prime targets for p53 gene transfer mediated by a recombinant adeno-associated virus type-2 vector.

Rohr UP, Wulf MA, Stahn S, Heyd F, Steidl U, Fenk R, Opalka B, Pitschke G, Prisack HB, Bojar H, Haas R, Kronenwett R.

Cancer Gene Ther. 2003 Dec;10(12):898-906.

PMID:
14712316
32.
33.

Apoptotic genes in cancer therapy.

Opalka B, Dickopp A, Kirch HC.

Cells Tissues Organs. 2002;172(2):126-32. Review.

PMID:
12426489
34.

A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.

Elmaagacli AH, Runkel K, Steckel N, Opalka B, Trenschel R, Seeber S, Schaefer UW, Beelen DW.

Bone Marrow Transplant. 2001 Apr;27(8):809-15.

38.

Type and position of promoter elements in retroviral vectors have substantial effects on the expression level of an enhanced green fluorescent protein reporter gene.

Flasshove M, Bardenheuer W, Schneider A, Hirsch G, Bach P, Bury C, Moritz T, Seeber S, Opalka B.

J Cancer Res Clin Oncol. 2000 Jul;126(7):391-9.

PMID:
10929761
39.
40.

Transformation-defective adenovirus 5 E1A mutants exhibit antioncogenic properties in human BLM melanoma cells.

Dickopp A, Esche H, Swart G, Seeber S, Kirch HC, Opalka B.

Cancer Gene Ther. 2000 Jul;7(7):1043-50.

41.

Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expression.

Werner NS, Siprashvili Z, Fong LY, Marquitan G, Schröder JK, Bardenheuer W, Seeber S, Huebner K, Schütte J, Opalka B.

Cancer Res. 2000 Jun 1;60(11):2780-5.

42.

The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma.

Ren S, Smith MJ, Louro ID, McKie-Bell P, Bani MR, Wagner M, Zochodne B, Redden DT, Grizzle WE, Wang Nd, Smith DI, Herbst RA, Bardenheuer W, Opalka B, Schütte J, Trent JM, Ben-David Y, Ruppert JM.

Oncogene. 2000 Mar 9;19(11):1419-27.

44.
45.

Loss of expression of the DRR 1 gene at chromosomal segment 3p21.1 in renal cell carcinoma.

Wang L, Darling J, Zhang JS, Liu W, Qian J, Bostwick D, Hartmann L, Jenkins R, Bardenhauer W, Schutte J, Opalka B, Smith DI.

Genes Chromosomes Cancer. 2000 Jan;27(1):1-10.

PMID:
10564580
46.

Novel tumor suppressor locus in human chromosome region 3p14.2.

Jülicher K, Marquitan G, Werner N, Bardenheuer W, Vieten L, Bröcker F, Topal H, Seeber S, Opalka B, Schütte J.

J Natl Cancer Inst. 1999 Sep 15;91(18):1563-8.

PMID:
10491433
47.

Assignment of human filamin gene FLNB to human chromosome band 3p14.3 and identification of YACs containing the complete FLNB transcribed region.

Bröcker F, Bardenheuer W, Vieten L, Jülicher K, Werner N, Marquitan G, Michael D, Opalka B, Schütte J.

Cytogenet Cell Genet. 1999;85(3-4):267-8. No abstract available.

PMID:
10449914
49.

Frequency of clonal B lymphocytes in chronic myelogenous leukemia evaluated by fluorescence in situ hybridization.

al-Amin A, Lennartz K, Runde V, Seeber S, Opalka B, Kloke O.

Cancer Genet Cytogenet. 1998 Jul 1;104(1):45-7.

PMID:
9648557
50.

Minimal deletion of 3p13-->14.2 associated with immortalization of human uroepithelial cells.

Vieten L, Belair CD, Savelieva L, Jülicher K, Bröcker F, Bardenheuer W, Schütte J, Opalka B, Reznikoff CA.

Genes Chromosomes Cancer. 1998 Jan;21(1):39-48.

PMID:
9443040

Supplemental Content

Loading ...
Support Center